| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-05-2097 |
| P698 | PubMed publication ID | 16510597 |
| P50 | author | Pierre-Francois Cartron | Q47825730 |
| P2093 | author name string | François M Vallette | |
| Philippe Juin | |||
| Fabien Gautier | |||
| Olivier Geneste | |||
| Tristan Gallenne | |||
| René Grée | |||
| Nicolas Cauquil | |||
| Florence Manero | |||
| Danielle Grée | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell death | Q2383867 |
| P304 | page(s) | 2757-2764 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death | |
| P478 | volume | 66 |
| Q42868172 | ABT-737 and/or folate reverse the PDGF-induced alterations in the mitochondrial apoptotic pathway in low-grade glioma patients |
| Q38797521 | Anti-leukemic, anti-lung, and anti-breast cancer potential of the microbial polyketide 2, 4-diacetylphloroglucinol (DAPG) and its interaction with the metastatic proteins than the antiapoptotic Bcl-2 proteins |
| Q38388106 | Antiapoptotic Bcl-2 protein as a potential target for cancer therapy: A mini review |
| Q44448455 | Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells |
| Q24655483 | BH3 mimetics to improve cancer therapy; mechanisms and examples |
| Q39617756 | Bax activation by engagement with, then release from, the BH3 binding site of Bcl-xL. |
| Q37237621 | Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members |
| Q35013101 | Bcl-2 inhibitor HA14-1 and genistein together adeptly down regulated survival factors and activated cysteine proteases for apoptosis in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells |
| Q35013095 | Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways |
| Q24635408 | Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy |
| Q39690679 | Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death |
| Q36483749 | Broad targeting of resistance to apoptosis in cancer. |
| Q40011683 | CPT21, a novel compound with anti-proliferative effect against gastric cancer cell SGC7901. |
| Q37079878 | Chemoresistance in gliomas |
| Q28535295 | Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression |
| Q38117157 | Developments in the use of nanocapsules in oncology |
| Q39832035 | Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. |
| Q38961466 | EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. |
| Q46866934 | Effect of HA14-1 on apoptosis-regulating proteins in HeLa cells |
| Q33682689 | Emerging Bcl-2 inhibitors for the treatment of cancer |
| Q37124747 | Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents |
| Q39134027 | Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells. |
| Q41851973 | How can we kill cancer cells: Insights from the computational models of apoptosis |
| Q38626416 | How to train glioma cells to die: molecular challenges in cell death |
| Q59121341 | In Silico Molecular Docking Analysis of Natural Pyridoacridines as Anticancer Agents |
| Q37077640 | Induction of apoptosis by fucoidan in human leukemia U937 cells through activation of p38 MAPK and modulation of Bcl-2 family |
| Q35207881 | Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma. |
| Q64233388 | Inhibition of NET-1 suppresses proliferation and promotes apoptosis of hepatocellular carcinoma cells by activating the PI3K/AKT signaling pathway |
| Q44357715 | Low probability activation of Bax/Bak can induce selective killing of cancer cells by generating heterogeneity in apoptosis |
| Q30502341 | MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents |
| Q34775350 | Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). |
| Q39359970 | MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide |
| Q36668047 | Mitochondrial permeability transition pore as a selective target for anti-cancer therapy |
| Q35036609 | Morpholino artifacts provide pitfalls and reveal a novel role for pro-apoptotic genes in hindbrain boundary development |
| Q47845813 | Natural Bioactive Compounds: Alternative Approach to the Treatment of Glioblastoma Multiforme |
| Q36670682 | Promotion of PDT efficacy by a Bcl-2 antagonist |
| Q33574535 | REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy |
| Q51819975 | Regulation of HA14-1 mediated oxidative stress, toxic response, and autophagy by curcumin to enhance apoptotic activity in human embryonic kidney cells. |
| Q34399676 | Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. |
| Q37761935 | Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics |
| Q28543401 | Synthesis and characterization of novel 2-amino-chromene-nitriles that target Bcl-2 in acute myeloid leukemia cell lines |
| Q83158104 | Targeting mitochondria for cancer therapy |
| Q34115304 | Targeting mitochondria for cancer therapy |
| Q26866936 | Targeting the Bcl-2 family for cancer therapy |
| Q39413089 | The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells |
| Q39466656 | The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells |
| Q35180339 | The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment |
| Q26827928 | The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma |
| Q26851645 | The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond |
| Q35387486 | p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis |
| Q40150613 | sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell |
Search more.